Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective study.
Nishibori Y, Kenmotsu H, Ando K, Tonsho A, Matsuda S, Morita M, Sekikawa M, Doshita K, Morikawa N, Miura K, Kodama H, Yabe M, Iida Y, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Ono A, Naito T, Murakami H, Harada H, Takahashi T. Nishibori Y, et al. Among authors: wakuda k. Cancer Treat Res Commun. 2024;41:100849. doi: 10.1016/j.ctarc.2024.100849. Epub 2024 Nov 8. Cancer Treat Res Commun. 2024. PMID: 39536390 Free article.
Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy.
Kobayashi H, Naito T, Omae K, Omori S, Nakashima K, Wakuda K, Ono A, Kenmotsu H, Murakami H, Endo M, Harada H, Takahashi T. Kobayashi H, et al. Among authors: wakuda k. J Cancer. 2018 May 22;9(11):2054-2060. doi: 10.7150/jca.24936. eCollection 2018. J Cancer. 2018. PMID: 29896291 Free PMC article.
Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer.
Inoue H, Ono A, Kawabata T, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Wakuda K, Kenmotsu H, Naito T, Murakami H, Yasui K, Ogawa H, Onoe T, Endo M, Harada H, Takahashi T. Inoue H, et al. Among authors: wakuda k. Invest New Drugs. 2020 Oct;38(5):1612-1617. doi: 10.1007/s10637-020-00917-2. Epub 2020 Mar 3. Invest New Drugs. 2020. PMID: 32128667 Free PMC article.
Proposing synchronous oligometastatic non-small-cell lung cancer based on progression after first-line systemic therapy.
Miyawaki T, Wakuda K, Kenmotsu H, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ono A, Naito T, Murakami H, Notsu A, Mori K, Harada H, Endo M, Ohde Y, Takahashi K, Takahashi T. Miyawaki T, et al. Among authors: wakuda k. Cancer Sci. 2021 Jan;112(1):359-368. doi: 10.1111/cas.14707. Epub 2020 Nov 11. Cancer Sci. 2021. PMID: 33098119 Free PMC article.
Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer.
Nishioka N, Naito T, Notsu A, Mori K, Kodama H, Miyawaki E, Miyawaki T, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Murakami H, Takayama K, Takahashi T. Nishioka N, et al. Among authors: wakuda k. Cancer Med. 2021 Jan;10(1):247-256. doi: 10.1002/cam4.3631. Epub 2020 Dec 10. Cancer Med. 2021. PMID: 33300678 Free PMC article.
Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.
Mamesaya N, Muramatsu K, Yabe M, Kodama H, Nishioka N, Miyawaki T, Miyawaki E, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Naito T, Murakami H, Harada H, Sugino T, Shimizu T, Gon Y, Takahashi T. Mamesaya N, et al. Among authors: wakuda k. Int J Clin Oncol. 2021 Apr;26(4):659-669. doi: 10.1007/s10147-020-01856-x. Epub 2021 Jan 7. Int J Clin Oncol. 2021. PMID: 33415571
Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation.
Kodama H, Kenmotsu H, Kawabata T, Notsu A, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Takahashi T. Kodama H, et al. Among authors: wakuda k. Cancer Med. 2021 Nov;10(21):7503-7513. doi: 10.1002/cam4.4268. Epub 2021 Sep 29. Cancer Med. 2021. PMID: 34587359 Free PMC article.
Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer.
Nishimura A, Ono A, Wakuda K, Kawabata T, Yabe M, Miyawaki T, Miyawaki E, Kodama H, Nishioka N, Mamesaya N, Kobayashi H, Omori S, Kenmotsu H, Naito T, Murakami H, Harada H, Takahashi T. Nishimura A, et al. Among authors: wakuda k. Invest New Drugs. 2022 Apr;40(2):403-410. doi: 10.1007/s10637-021-01191-6. Epub 2021 Oct 11. Invest New Drugs. 2022. PMID: 34633575 Free PMC article.
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.
Miyawaki T, Kenmotsu H, Kodama H, Nishioka N, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ko R, Wakuda K, Ono A, Naito T, Murakami H, Mori K, Harada H, Endo M, Takahashi K, Takahashi T. Miyawaki T, et al. Among authors: wakuda k. BMC Cancer. 2021 Nov 19;21(1):1247. doi: 10.1186/s12885-021-08983-2. BMC Cancer. 2021. PMID: 34798865 Free PMC article.
131 results